$3.05
0.33%
Downside
Day's Volatility :3.34%
Upside
3.02%
83.61%
Downside
52 Weeks Volatility :87.28%
Upside
22.39%
Period | Heron Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 26.53% | 6.5% | 0.0% |
6 Months | 24.5% | 7.1% | 0.0% |
1 Year | 87.88% | 9.8% | 0.0% |
3 Years | -75.3% | 14.2% | -20.2% |
Market Capitalization | 474.6M |
Book Value | - $0.22 |
Earnings Per Share (EPS) | -0.55 |
PEG Ratio | -0.18 |
Wall Street Target Price | 6.75 |
Profit Margin | -61.28% |
Operating Margin TTM | -13.84% |
Return On Assets TTM | -18.45% |
Return On Equity TTM | -2408.88% |
Revenue TTM | 132.1M |
Revenue Per Share TTM | 0.9 |
Quarterly Revenue Growth YOY | 17.1% |
Gross Profit TTM | -50.5M |
EBITDA | -61.9M |
Diluted Eps TTM | -0.55 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.11 |
EPS Estimate Next Year | 0.01 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.07 |
What analysts predicted
Upside of 121.31%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 77.5M | ↑ 151.81% |
Net Income | -178.8M | ↓ 9.44% |
Net Profit Margin | -230.84% | ↑ 411.03% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 146.0M | ↑ 88.41% |
Net Income | -204.7M | ↑ 14.49% |
Net Profit Margin | -140.27% | ↑ 90.57% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 88.6M | ↓ 39.28% |
Net Income | -224.4M | ↑ 9.61% |
Net Profit Margin | -253.2% | ↓ 112.93% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 86.3M | ↓ 2.59% |
Net Income | -217.7M | ↓ 3.02% |
Net Profit Margin | -252.08% | ↑ 1.12% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 107.7M | ↑ 24.7% |
Net Income | -134.5M | ↓ 38.2% |
Net Profit Margin | -124.93% | ↑ 127.15% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 127.0M | ↑ 17.99% |
Net Income | -110.6M | ↓ 17.81% |
Net Profit Margin | -87.02% | ↑ 37.91% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 30.0M | ↑ 13.07% |
Net Income | -27.2M | ↓ 35.11% |
Net Profit Margin | -90.61% | ↑ 67.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 29.6M | ↓ 1.38% |
Net Income | -32.5M | ↑ 19.35% |
Net Profit Margin | -109.65% | ↓ 19.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.8M | ↑ 7.25% |
Net Income | -42.1M | ↑ 29.52% |
Net Profit Margin | -132.42% | ↓ 22.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.4M | ↓ 1.03% |
Net Income | -25.0M | ↓ 40.54% |
Net Profit Margin | -79.56% | ↑ 52.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.2M | ↑ 8.9% |
Net Income | -10.7M | ↓ 57.12% |
Net Profit Margin | -31.33% | ↑ 48.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 34.7M | ↑ 1.28% |
Net Income | -3.2M | ↓ 70.53% |
Net Profit Margin | -9.11% | ↑ 22.22% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 462.2M | ↑ 97.25% |
Total Liabilities | 92.0M | ↓ 10.81% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 512.8M | ↑ 10.95% |
Total Liabilities | 108.9M | ↑ 18.4% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 353.6M | ↓ 31.05% |
Total Liabilities | 117.1M | ↑ 7.45% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 305.7M | ↓ 13.53% |
Total Liabilities | 228.1M | ↑ 94.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 251.0M | ↓ 17.91% |
Total Liabilities | 237.4M | ↑ 4.05% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 222.5M | ↓ 11.33% |
Total Liabilities | 256.5M | ↑ 8.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 251.0M | ↓ 7.72% |
Total Liabilities | 237.4M | ↓ 4.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 220.9M | ↓ 11.98% |
Total Liabilities | 232.3M | ↓ 2.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 201.2M | ↓ 8.9% |
Total Liabilities | 240.5M | ↑ 3.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 229.2M | ↑ 13.9% |
Total Liabilities | 257.0M | ↑ 6.85% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 222.5M | ↓ 2.92% |
Total Liabilities | 256.5M | ↓ 0.2% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 217.9M | ↓ 2.08% |
Total Liabilities | 251.7M | ↓ 1.88% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -191.8M | ↑ 12.63% |
Investing Cash Flow | -278.6M | ↓ 3699.77% |
Financing Cash Flow | 357.6M | ↑ 21.75% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.6M | ↓ 35.05% |
Investing Cash Flow | -21.8M | ↓ 92.18% |
Financing Cash Flow | 186.4M | ↓ 47.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -184.8M | ↑ 48.35% |
Investing Cash Flow | 209.0M | ↓ 1059.26% |
Financing Cash Flow | 9.1M | ↓ 95.12% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -203.4M | ↑ 10.03% |
Investing Cash Flow | 32.7M | ↓ 84.34% |
Financing Cash Flow | 156.0M | ↑ 1613.65% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -146.9M | ↓ 27.76% |
Investing Cash Flow | -3.3M | ↓ 110.16% |
Financing Cash Flow | 75.1M | ↓ 51.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -37.5M | ↑ 1.26% |
Investing Cash Flow | 2.0M | ↓ 105.61% |
Financing Cash Flow | 439.0K | ↓ 99.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.9M | ↓ 33.66% |
Investing Cash Flow | 36.8M | ↑ 1722.56% |
Financing Cash Flow | -208.0K | ↓ 147.38% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -27.2M | ↑ 9.1% |
Investing Cash Flow | 13.2M | ↓ 64.11% |
Financing Cash Flow | 319.0K | ↓ 253.37% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.2M | ↓ 66.21% |
Investing Cash Flow | -23.2M | ↓ 275.68% |
Financing Cash Flow | 53.8M | ↑ 16764.26% |
Sell
Neutral
Buy
Heron Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Heron Therapeutics, Inc. | -6.91% | 24.5% | 87.88% | -75.3% | -82.53% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Heron Therapeutics, Inc. | NA | NA | -0.18 | -0.11 | -24.09 | -0.18 | NA | -0.22 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Heron Therapeutics, Inc. | Buy | $474.6M | -82.53% | NA | -61.28% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Heron Therapeutics, Inc.
Revenue is up for the last 3 quarters, 31.43M → 34.67M (in $), with an average increase of 4.7% per quarter
Netprofit is up for the last 4 quarters, -42.05M → -3.16M (in $), with an average increase of 146.9% per quarter
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 261.8%
Rubric Capital Management LP
Orbimed Advisors, LLC
Vanguard Group Inc
BlackRock Inc
Velan Capital Investment Management LP
Franklin Resources Inc
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Organization | Heron Therapeutics, Inc. |
Employees | 126 |
CEO | Mr. Craig Alexander Collard |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.05
-1.61%
Keyarch Acquisition Corp
$3.05
-1.61%
Connexa Sports Technologies Inc
$3.05
-1.61%
Us Value Etf
$3.05
-1.61%
First Wave Biopharma Inc
$3.05
-1.61%
Global X Msci Next Emerging
$3.05
-1.61%
Fat Projects Acquisition Corp
$3.05
-1.61%
Capital Link Global Fintech
$3.05
-1.61%
Applied Uv Inc
$3.05
-1.61%